Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain by Jose Martinez-Raga et al.
RESEARCH Open Access
Budgetary impact analysis of buprenorphine-
naloxone combination (Suboxone®) in Spain
Jose Martinez-Raga1, Francisco Gonzalez-Saiz2, Julian Oñate3, Itziar Oyagüez4*, Eliazar Sabater4 and
Miguel A Casado4
Abstract
Background: Opioid addiction is a worldwide problem. Agonist opioid treatment (AOT) is the most widespread
and frequent pharmacotherapeutic approach. Methadone has been the most widely used AOT, but buprenorphine,
a partial μ-opiod agonist and a -opiod antagonist, is fast gaining acceptance. The objective was to assess the
budgetary impact in Spain of the introduction of buprenorphine-naloxone (B/N) combination.
Methods: A budgetary impact model was developed to estimate healthcare costs of the addition of B/N
combination to the therapeutic arsenal for treating opioid dependent patients, during a 3-year period under the
National Health System perspective. Inputs for the model were obtained from the specialized scientific literature.
Detailed information concerning resource consumption (drug cost, logistics, dispensing, medical, psychiatry and
pharmacy supervision, counselling and laboratory test) was obtained from a local expert panel. Costs are expressed
in euros (€, 2010).
Results: The number of patients estimated to be prescribed B/N combination was 2,334; 2,993 and 3,589 in the
first, second and third year respectively. Total budget is €85,766,129; €79,855,471 and €79,137,502 in the first,
second and third year for the scenario without B/N combination. With B/N combination the total budget would be
€86,589,210; €80,398,259 and €79,708,964 in the first, second and third year of the analyses. Incremental cost/
patient comparing the addition of the B/N combination to the scenario only with methadone is €10.58; €6.98 and
€7.34 in the first, second and third year respectively.
Conclusion: Addition of B/N combination would imply a maximum incremental yearly cost of €10.58 per patient
compared to scenario only with methadone and would provide additional benefits.
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Background
Opioid abuse remains a serious public health problem
worldwide, notably in Asia and Europe. Worldwide pre-
valence of opioid use has been estimated at 0.4% [1]. In
Spain, the most recent available data indicated that 0.8%
of the population aged 15-64 used opioids in 2007 [2].
Opioid addiction is associated with great economic bur-
den [3], as well as various and severe health problems,
including an increased risk for HIV/AIDS and viral
hepatitis B and C infection, generally as a consequence
of intravenous drug use. Mortality rates are high as well,
particularly among individuals 15-34 years of age [4].
Mortality in dependent heroin users is between 6 and
20 times that expected for the general population of the
same age and gender. As a consequence, in many coun-
tries, opioid use constitutes the main cause of drug-
related deaths [1].
Pharmacological interventions for heroin dependence
aim primarily at maximizing treatment retention, attain-
ing long-term abstinence and minimizing the risk of
returning to the previous pattern of drug abuse follow-
ing safe and efficient suppression of opioid withdrawal
symptoms [5,6]. Different types of medications are used
in the management of opioid dependent patients,
including opioid agonists and partial agonists, opioid
antagonists and alpha (2)-adrenergic agonists [6-8].
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Agonist opioid treatment (AOT) is the most common
intervention for heroin dependence [9]. Methadone, as
part of an AOT program, is the most widely used and
well researched pharmacotherapy for heroin dependent
patients since the 1960s [10]. However, other agonists
alone or in combination with antagonist compounds are
increasingly used [9].
Buprenorphine, a partial μ-opiod receptor agonist and a
-opiod receptor antagonist, is fast gaining acceptance
among addiction specialists and patients [10-12], partly
due to methadone, as the sole available AOT in most
countries fails to meet the specific treatment needs of all
opioid-dependent individuals who might benefit from
medication. This may help to explain why a significant
proportion of these patients remain untreated [13]. Solid
evidence has shown the efficacy of buprenorphine for
treating heroin addiction [8,14-16]. A buprenorphine/
naloxone (B/N) combination (Suboxone®, Reckitt Beckin-
ser Pharmaceuticals Limited) was approved by the Eur-
opean Medicines Agency (EMA) in September 2006 as
oral substitution treatment for opioid drug dependence
within a framework of medical, social and psychological
treatment [17]. The rationale for developing a new com-
pound, combining naloxone with buprenorphine was to
minimize the risk of intravenous misuse. Injection of
naloxone would precipitate opioid withdrawal in opioid-
dependent patients, but taken sublingually, as prescribed,
the bioavailability of naloxone is negligible, therefore
allowing for the patient to benefit from effects of bupre-
norphine alone [18,19]. As a result of the reduced risk for
diversion and misuse there is less need for direct close
supervision of medication during OST, less resources
involved therefore allowing for a reduction in associated
costs and for treatment to become more accessible [20]. In
addition, there is evidence that buprenorphine/naloxone is
an effective and well-tolerated treatment for medically
assisted opioid withdrawal when the dosage is titrated to
achieve good control of withdrawal symptoms [21,22].
Additionally to the primary outcomes on efficacy/
effectiveness and safety, the results provided in eco-
nomic evaluations (cost-effectiveness and budgetary
impact) could be a crucial source to be used by health
care provider for the purpose of decision making [23].
Budgetary impact studies are a direct tool for helping
decision makers to perform a better allocation of avail-
able resources, mainly in the present global situation of
cost constraint we are living.
The aim of this study was to assess the budgetary
impact in Spain of buprenorphine-naloxone (B/N) com-
bination (Suboxone®) as a newly approved pharma-
cotherapy for opioid dependence, specifically compared




A previous published [24] budgetary impact model using
Microsoft Excel 2003 following the international recom-
mendations [25-28] has been updated to estimate
healthcare costs of the approval of B/N combination as
a pharmacotherapy for opioid dependence. A decision
tree [29] based on an expert panel consensus was
devised to describe progress-over-time of patients in
AOT. (Figure 1) Simulation of events and outcomes
within the therapeutic strategies assessed were repre-
sented with as many arms as possible available options
for the different populations taken into account. For
each possible outcome or decision-tree-arm and for
each treatment option, the corresponding probabilities
of transition were estimated. The transition probabilities
used in the simulation, as obtained from a literature
review [24], are summarized in Table 1. Opinion of the
expert panel was sought for missing or controversial
information. The initial probabilities for the first year
were maintained in subsequent cycles.
Population
Eligible population was obtained from estimates of
National Program on Drugs [30]. Approval of B/N have
not increased the total annual population in AOT, con-
sequently the number of patients remained unchanged
throughout the simulation.
In concordance with previous studies three target
population groups were identified among the total eligi-
ble population [24]:
1) Patients needing medically assisted withdrawal
(MAW) program prior to entering a relapse prevention
program, therefore not in AOT.
2) Patients in high threshold programs (HTP). These
included those individuals without any physical or psy-
chological impairment, and despite showing good adher-
ence to AOT have difficulties in staying abstinent.
These patients require high levels of supervision.
3) Patients in low-intermediate threshold program
(LITP) were those with some physical and/or psycholo-
gical impairment and poor adherence to AOT. These
patients have less supervision and more commonly are
poly-substances abusers.
In the base case of the model, the first year of the
simulation begins with no patients on MAW stage.
According the expert panel opinion, in the first year
30.0% of patients are HTP and 70.0% are LITP.
Treatment options
Two pharmacotherapies were considered in the analysis:
methadone and B/N combination. Although the opioid
antagonist naltrexone was also available as a treatment
Martinez-Raga et al. Health Economics Review 2012, 2:3
http://www.healtheconomicsreview.com/content/2/1/3
Page 2 of 9
option for relapse prevention for heroin dependent sub-
jects, this medication was excluded from the analysis due
its limited acceptance among both patients and clinicians
[31] and the lack of sufficient evidence supporting its use
as a maintenance therapy for opioid dependence [32].
An expected 10.0%, 15.0% and 20.0% of patients enter-
ing B/N combination were considered in the model in
the first second and third year, respectively, in the HTP
group. It was assumed that all patients in LITP would
remain on methadone treatment. Two scenarios were
compared in the analysis: a situation with 100.0% of
patients in AOT treated with methadone versus an
alternative option considering annual gradual increases
of patients entering B/N combination.
Time horizon, perspective and discounting
The analysis was performed with a 3-year time projec-
tion with 3 cycles of 1 year each within the context of
the National Health System. However, considering that
in Spain addiction treatment programs and services are
organized and developed by Autonomous Regional Gov-
ernments, results are shown by Autonomous Regions, as
well.
As stated in the good practices of the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) [26], budget impact analyses present financial
streams over time, and it is not necessary to discount
the costs.
Resources and costs
The following resources and treatment components
were identified and quantified:
Figure 1 Diagram representation of the decision tree.
Table 1 Transition probabilities
From: MAW HTP LITP
To: Methadone B/N
MAW 50.0% 5.0% 18.0% 0.0%
HTP 35.0% 75.0% 63.0% 5.0%
LITP 15.0% 20.0% 19.0% 95.0%
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1) Drug costs: Pharmacological costs of the pharma-
cotherapies evaluated that were calculated based on
defined daily dose as established by the World Health
Organization [33] and expert panel opinion. An average
daily dose of 8 mg per patient was considered for B/N
combination, and of 60 mg for methadone (indepen-
dently of whether patients were HTP or LITP).
2) Logistic costs: Distribution and production resources
were considered. These included a series of procedures
generally performed by an accredited pharmacist such
as collecting and storing methadone with adequate
safety measures, transporting the methadone to central
pharmacies for individual methadone hydrochloride
dose preparation, subsequent distribution to the dispen-
sing centres, and finally collection of unused doses. An
average of four minutes per methadone dose for distri-
bution and 2 minutes per methadone dose for produc-
tion were considered for the purpose of cost estimation.
No logistics resources were involved in B/N
combination.
3) Dispensing: Five minutes of nursing staff for dispen-
sing methadone to patients was considered in the analy-
sis. Methadone dispensing twice a week was taken into
account in HTP patients for the first year (104 dispensa-
tions) and once a week for the second and third year (52
dispensations per year). Once a week dispensing was
considered for LITP patients. No dispensing was
required in the case of B/N combination treatment. In
addition, it was assumed that 36 dispensation (associated
with non-AOT drugs) per year are needed in MAW
patients.
4) Medical, psychiatry and pharmacy staff involve-
ment: Medical supervision (15 minutes) is required for
patients in AOT. Ten visits by year in MAW and HTP
patients and 6 visits by year in LITP. For psychiatric
care 10 sessions (25 minutes/session) were assumed in
MAW and first year of treatment in HTP. Ten sessions
by year was also assumed for 2nd and 3rd year in HTP
methadone treated patients. Five sessions by year for 2nd
and 3rd year in patients treated with B/N combination.
No psychiatric care for LITP patients was included.
Pharmacy supervision (1 minute) is estimated to be
done 36 times by year in MAW patients, and daily in
HTP and LITP.
5) Counselling: Twenty-five minutes sessions with spe-
cialist addiction of psychologist were also included in
the analysis. A total of 20 sessions/year for MAW and
first year of treatment for HTP patients was assumed,
whilst for each of the second and third year the number
of estimated sessions was 10 for methadone treated
patients and 5 for patients treated with B/N combina-
tion. In addition, the assumption was made that LITP
patients would not be involved in specialist psychologi-
cal counselling. Social and employment rehabilitation
care (15 minutes per session) provided by social workers
to individuals in AOT was also taken into account. (See
Table 2 for detailed social worker assistance)
6) Laboratory test: Urine toxicology drug screenings
were also included in the analysis.
All costs are expressed in euros (€, 2010). Resource
unitary costs (Table 3) were collected from literature
[24] and a Spanish costs database updated to 2010 value
with Consumer Price Index [34]. Concerning pharmaco-
logical costs, the ex-factory prices of medications were
considered. The 7.5% reduction of ex-factory price
required by Health Authorities was applied to B/N com-
bination [35].
Sensitivity analyses
One-way sensitivity analyses were performed to test the
robustness of the model. Base case values were modified
for the following parameters:
-Transition probabilities: The same values applied for
methadone were also assumed for B/N combination.
-Patients commencing B/N combination: In Spain
there is only an Autonomous Region (Murcia) where B/
Table 2 Resource consumption
HTP LITP
Resource MAW Methadone 1st year Methadone 2
nd
& 3
rd year B/N 1st year B/N 2
nd
& 3
rd year Methadone B/N
Distribution 365 365
Production 365 365 365
Dispensing 36 104 52 52
Supervision
drug-pharmacy 36 365 365 365
medical/clinical 6 6
psychological 20 20 10 20 5
social worker 15 10 10 10 5 6 6
psychiatric 10 10 10 10 5
Monitoring (analytical controls) 36 12 12 12
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N combination is fully financed by the Regional Health
Care System with a free access to the drug. A sensitivity
analysis with the proportion of patients starting B/N
combination treatment over the previous three years
available for this region was performed (0.97%, 2.57%
and 3.83%) [36]
-Initial distribution of patients: Influence of 100% of
patients in LITP or 100% of patients in HTP was tested.
-Resource costs: Differences of ± 10% in cost per min-
ute of resources were tested.
Results
Treatment population: patients on AOT programs
According to National Health estimates of the Spanish
National Program on Drugs [30], a total of 77,811
patients were calculated to be enrolled in AOT.
According to patient distribution within each target
group and the projection of the percentage of specific
AOT medication use over the three years of the study
period, the number of patients expected to be treated
with B/N combination during the first, second and third
year of the study was 2,334; 2,993 and 3,589, respec-
tively. The simulation in the defined base case begins
with 30.0% of the total population in HTP. In the sce-
nario without B/N combination, a total of 1,167 patients
progressed to MAW in the 2nd year and 1,595 in 3rd
year. Addition of B/N combination was associated with
1,466 and 2,114 MAW patients in the first and second
year.
Budgetary impact
Total budgetary impact was €85,766,129, €79,855,471
and €79,137,502 in first, second and third year, respec-
tively, for the scenario without B/N combination. In
contrast, with the availability of B/N combination the
total budgetary impact would be €86,589,210,
€80,398,259 and €79,708,964 in the first, second and
third year of the analyses, respectively (Table 4).
Detailed results by Spanish Autonomous Regions are
shown in Table 5.
Sensitivity analysis
In the sensitivity analysis, distribution of patients in
HTP or LITP groups was the most influential parameter
on the results. Incremental differences in cost/patient
could reach a total of €35.26, €19.13 and €16.46 in the
first, second and third year of the study, respectively,
assuming that 100% of the population was in HTP
group at the beginning of the simulation. On the other
hand, if it was to be assumed that 100% of the popula-
tion was in the LITP group at the beginning of the
study, the incremental cost associated to B/N combina-
tion compared to a situation where methadone is the
sole available AOT would be €0, €1.76 and €3.44 per
patient for the first, second and third year, respectively.
Detailed results are shown in Table 6.
When the number of patients commencing B/N com-
bination from the Murcia Region is applied to national
Table 3 Unitary costs (€, 2010)
Resource Cost (€, 2010)
Drugs
Methadone 531.80 € per
methadone kg
Buprenorphine/Naloxone combination













Monitoring (analytical controls) 3.81€/test
Table 4 Budgetary impact results (€, 2010)
Scenario without B/N combination Scenario with B/N combination Difference (€) with B/N vs. without B/N
1st year MAW 1,724,290 2,312,217 587,927
HTP 28,428,367 28,541,622 113,255
LITP 55,613,472 55,735,372 121,900
2nd year MAW 1,711,926 2,416,973 705,047
HTP 22,380,263 22,181,969 -198,294
LITP 55,763,283 55,799,317 36,034
3rd year MAW 1,747,500 2,642,079 894,579
HTP 20,796,602 20,476,162 -320,440
LITP 56,593,400 56,590,723 -2,677
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level the incremental total budgetary impact of AOT in
the scenario with B/N combination versus scenario
without B/N combination was €79.839, €106,513 and
€122,872 for the first, second and third year. Differences
in cost per patient between the 2 scenarios are €1.03,
€1.37 and €1.58 for each of the three years.
Discussion
The results from the present study show that approval
of a novel medication for heroin dependent patients,
namely B/N combination compared to the only AOT
available, methadone, is associated with increases in
direct pharmacological costs, but it is also directly asso-
ciated with reduction of other type of costs involved, as
analysed, including logistics/distribution, production,
delivery, supervision and monitoring.
According to the results of the sensitivity analysis, the
parameters with the most influence on the final out-
comes would be those associated with patient profile
and percentage of B/N combination use. The number of
patients commencing B/N combination each year, used
in the sensitivity analysis, was obtained from a market
sales database [36], representing real use of B/N combi-
nation in a specific region in Spain (Murcia). Base case
is a conservative approach to the approval of B/N com-
bination, as intake values used are higher than real life
values. If market conditions of Murcia are extrapolated
to national level the total budgetary impact per patient
would be €1.03, €1.37 and €1.58 for the first, second
and third year of the analysis.
These results are in concordance with those obtained
in the previous publication of the original model [24].
The present work is an update as much the current
situation in terms of number of patients as costs.
Besides, this paper provides more details of the resource
consumption and more accurate estimates of the bud-
getary impact, based on data following the real use of B/
N combination.
The model developed for the analysis aims to be a
transparent tool. All the parameters included and
assumptions considered are presented in such a detailed
manner to allow for replication in similar or different
settings. Third payer perspective was chosen to provide
useful data for the decision makers at the funding
administration level.
There are several limitations to be considered in this
model, including the very limited number of published
reports regarding resource consumption in population
Table 5 Results by Autonomous Region
Region Eligible population Scenario without B/N
combination Budget impact (€)
Scenario with B/N combination
Budget impact (€)




















Andalucia 17,637 19,440,146 18,100,409 17,937,671 19,626,710 18,223,440 18,067,201 186,563 123,031 129,530
Aragon 1,362 1,501,246 1,397,786 1,385,219 1,515,653 1,407,287 1,395,222 14,407 9,501 10,003
Asturias 3,289 3,625,256 3,375,418 3,345,070 3,660,047 3,398,361 3,369,225 34,791 22,943 24,155
Baleares 2,541 2,800,783 2,607,764 2,584,318 2,827,662 2,625,490 2,602,980 26,879 17,725 18,662
Canary Islands 5,063 5,580,624 5,196,029 5,149,313 5,634,180 5,231,348 5,186,497 53,556 35,318 37,184
Cantabria 795 876,278 815,888 808,553 884,688 821,434 814,392 8,409 5,546 5,839
Castilla La Mancha 2,226 2,453,579 2,284,488 2,263,948 2,447,125 2,300,016 2,280,297 23,547 15,528 16,348
Castilla León 4,197 4,626,087 4,307,275 4,268,549 4,670,483 4,336,553 4,299,373 44,396 29,277 30,824
Catalonia 7,922 8,731,918 8,130,149 8,057,052 8,815,717 8,185,411 8,115,233 83,799 55,262 58,181
Extremadura 1,683 1,855,064 1,727,221 1,711,691 1,872,867 1,738,961 1,724,052 17,803 11,740 12,360
Galicia 7,822 8,621,694 8,027,522 7,955,347 8,704,435 8,082,086 8,012,794 82,741 54,564 57,447
Madrid 9,606 10,588,084 9,858,396 9,769,761 10,689,696 9,925,405 9,840,309 101,612 67,009 70,549
Murcia 2,021 2,227,620 2,074,101 2,055,453 2,248,998 2,088,199 2,070,296 21,378 14,098 14,843
Navarra 799 880,687 819,994 812,621 889,139 825,567 818,489 8,452 5,574 5,868
Basque Country 2,633 2,902,189 2,702,182 2,677,887 2,930,041 2,720,549 2,697,224 27,852 18,367 19,337
La Rioja 762 839,904 782,021 774,990 847,965 787,337 780,587 8,060 5,315 5,596
Valencia 6,425 7,081,870 6,593,816 6,534,532 7,149,833 6,638,635 6,581,718 67,963 44,819 47,187
Ceuta 603 664,649 618,844 613,280 671,027 623,050 617,708 6,379 4,206 4,429
Melilla 425 468,451 436,167 432,245 472,946 439,131 435,367 4,496 2,965 3,121
Total cost of AOT per patient was estimated at €1,102; €1,026 and €1,017 for the first, second and third year, respectively, in the scenario without B/N
combination. Incremental total cost per patient comparing the inclusion of the B/N combination to the scenario where methadone was the only medication
available, was €10.58, €6.98 and €7.34 in the first, second and third year, respectively. National budgetary impact by target population group for the 3 study
years is shown in Table 4.
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in AOT, and as a consequence analysis relied on expert
panel estimations. Pragmatic or naturalistic prospective
studies conducted under standard clinical practice,
designed to collect resources and costs data associated
to AOT could provide reliable information to be used in
further economic evaluations [37]. A potential limitation
of the model refers to the assumption that approval of
B/N combination would not cause a significant elevation
of the population entering AOT. An increase in the
number of patients entering in AOT was reported in
the UK when buprenorphine was licensed in the UK in
1999 [38], but early experiences in Spain following with
the approval of B/N combination does not suggest that
this could be expected [24,30]. Therefore to avoid con-
founding factors on the final results, it was decided to
keep a constant value for population under AOT. Poten-
tial improvements in quality of life and benefits resulting
from better integration at a social level were not
included in the present model, but there is evidence
that buprenorphine is associated to better results at psy-
chological, medical, family and work level than other
treatments [39]. A conservative approach has been cho-
sen for some aspects. Frequency of urine drug testing
remained unchanged with B/N combination, however it
would be expected a decrease in number of toxicological
screenings, with a subsequent reduction in associated
costs [40].
There is the common perception that methadone may
be more effective than buprenorphine for as an AOT,
primarily based on studies and experiences with low
buprenorphine doses and excessively slow induction
regimens as used in early buprenorphine trials [11,41].
However subsequent studies showed that the efficacy of
buprenorphine sublingual tablet or buprenorphine/
naloxone sublingual tablet (Suboxone®) is equivalent to
that of methadone when sufficient buprenorphine doses,
rapid induction, and flexible dosing are used [22,42,43].
Effectiveness has been also tested concluding that
buprenorphine is at least as effective as methadone and
has a better tolerability profile in reducing illicit opioid
when use in clinical practice [8,12,44]. Published evi-
dence have suggested that assuming that B/N combina-
tion is not more or less effective than methadone but it
will be less expensive in the long run, it is expected that
B/N combination would be more cost-effective than
methadone when provided to comparable groups of
patients [45]. Although methadone will remain an essen-
tial relapse prevention pharmacotherapy for opioid
addicted individuals, buprenorphine-based regimens
may increase access to care and provide safer, more
appropriate treatment than methadone for some
patients [11,44]. In addition buprenorphine is an alter-
native treatment for heroin dependent patients, espe-
cially for those who do not wish to start or continue
with methadone or for those who do not seem to bene-
fit from adequate dosages of methadone [46].
The budget impact analyses are important, along with
the cost-effectiveness analysis, as part of a comprehen-
sive economic evaluation of a new health technology
[26]. The purpose of a budget impact study is to esti-
mate the financial consequences of adoption and diffu-
sion of a new health-care intervention within a specific
health-care setting or system context given inevitable
resource constraints [26]. In Spain there are no official
threshold values published for health technologies
implementation. According to authors’ criteria, the
Table 6 Results of one-way sensitivity analyses.
Parameter
modified

























See table 1 Same values for B/N
combination than used for
methadone
1,102 1,026 1,017 1,113 1,035 1,028 10.58 9.18 11.13
B/N combination
uptakes
10%, 15% and 20%
for 1st, 2nd and 3rd
year
0.97%; 2.57% and 3.83% for
1st, 2nd and 3rd year




HTP: 30% and LITP:
70%
HTP: 100% 1,477 1,185 1,127 1,513 1,204 1,144 35.260 19.13 16.46
LITP: 100% 941 958 970 941 960 973 0 1.76 3.44
Resource cost
(cost per minute)
See table 3 +10% 1,201 1,126 1,116 1,218 1,129 1,119 7.78 2.87 2.30
-10% 995 926 918 1,008 937 930 13.38 11.08 12.39
Yearly budgetary impact per patient (€, 2010)
BC: Base Case; SA: Sensitivity analysis
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increases in total cost of AOT with B/N combination’s
incorporation obtained in this study seem reasonable,
even more if additional benefits at clinical level for
patients are considered.
The introduction of new (and expensive) pharmaceuti-
cal products is one of the major challenges for health
systems [47]. New treatments, procedures and technolo-
gies into the services’ portfolio of healthcare providers
should aim to improve three areas equally: patient
access to innovative solutions, the sustainability of the
health system and compensation for innovation. Tradi-
tional schemes based on fixed prices that fail to consider
the product’s appropriate use or its results in terms of
effectiveness may lead to inefficient decision-making
processes [48]. Risk-sharing agreements are defined as a
new form of contractual agreement between payers and
the pharmaceutical industry for setting the value of an
innovation conditional to demonstration of its effective-
ness and efficiency in real life [49]. This type of agree-
ments could be taken in mind when health authorities
face a regulatory decision on drug pricing and reimbur-
sement in a context of uncertainty [50], as they could
diminish the impact on the payer’s budget for new and
existing medicines brought about by either the uncer-
tainty of the value of the medicine and/or the need to
work within finite budgets [51].
Conclusions
Addition of B/N combination would imply a maximum
incremental yearly cost of €10.58 per patient compared
to scenario only with methadone and would provide
additional benefits
The results of this report would help the Regional and
National Authorities to perform a better allocation of
available resources associated to addiction treatment
services.
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